German pharmaceutical giant Bayer, which is facing a legal bid by generic drug maker Sandoz to invalidate patents covering blood clot drug Xarelto, is seeking to amend one of the patents in dispute.
Technology company Reflex Instruments has lost its challenge to rival Globaltech’s patent for two mining survey tools, with a judge finding Reflex had not established the technology wasn’t novel and lacked an inventive step.
Explosives manufacturer Orica is closer to taking Dyno Nobel to court for allegedly infringing three of its explosives patents, filing proceedings to get more information about its rival’s CyberDet wireless detonator device.
Real estate marketing platform Campaigntrack has won an appeal of a ruling in an important copyright case over its cloud-based software that accused real estate agency group Biggin & Scott of authorising reproduction of the software’s source code.
Nufarm Australia has successfully challenged a herbicide patent application by Dow Agrosciences’ successor on the grounds that the invention – aimed at limiting the worldwide problem of vapor drift – is neither new nor innovative.
Fintech startup Zeller Technologies has taken millennial financial adviser Victoria Devine to court after she succeeded in quashing its application to trade mark the word ‘Zeller’.
Western Australian energy company UON has won a bid to file amended claims in two Federal Court proceedings over a mining invention it says was stolen by a rival, after DLA Piper took over the cases from local firm Bennett + Co.
Korean drug company Samsung Bioepis has filed a second lawsuit seeking to invalidate German drug company Fresenius Kadi’s patent for a biosimilar of blockbuster arthritis drug Humira.
The conduct of Corrs Chambers Westgarth in the preparation of an ostensibly independent expert report in a trade secrets case “must not be repeated”, a judge has said, throwing out the expert’s evidence as potentially tainted by the law firm’s involvement.
Melbourne-based hard assets investment manager Merricks Capital has won undertakings from its ex-managing director and two former employees who defected to an investment boutique run by financial commentator Peter Switzer and his son Marty.